Mammoth Biosciences

Executive Summary

Mammoth Biosciences is a private, pre-clinical biotechnology company pioneering next-generation CRISPR-based genetic medicines. Founded in 2017 and headquartered in Brisbane, California, the company focuses on overcoming key delivery and efficacy challenges in in vivo gene editing by leveraging its proprietary protein discovery and engineering platform. This platform enables the identification and optimization of novel, ultracompact CRISPR-Cas systems, which are critical for efficient delivery via viral and non-viral vectors. Mammoth's mission is to develop permanent cures for serious diseases, initially targeting liver, central nervous system, and retinal indications. The company's approach is particularly differentiated by its small Cas effector proteins that can be packaged into single AAV vectors, addressing a major limitation in gene therapy. As a pre-clinical stage company, Mammoth's value hinges on its platform's ability to generate potent and specific editors that are deliverable in vivo, with a strong intellectual property portfolio and academic collaborations underpinning its progress.

Upcoming Catalysts (preview)

• H2 2026Lead Program IND Filing30% success
• H1 2026Major Pharmaceutical Partnership or Licensing Deal40% success
• Q2 2026Publication of Preclinical In Vivo Efficacy Data in a Peer-Reviewed Journal60% success